Shanghai Henlius Biotech, Inc. (HKG:2696)
Hong Kong · Delayed Price · Currency is HKD 84.10
+1.05 (1.26%)
Apr 17, 2026, 1:25 PM HKT
Shanghai Henlius Biotech Market Cap
Shanghai Henlius Biotech has a market cap or net worth of 45.14 billion as of April 16, 2026. Its market cap has increased by 172.30% in one year.
Market Cap
45.14B
Enterprise Value
48.20B
Revenue
7.42B
Ranking
n/a
PE Ratio
49.42
Stock Price
84.10
Market Cap Chart
Since September 25, 2019, Shanghai Henlius Biotech's market cap has increased from 26.66B to 45.14B, an increase of 69.31%. That is a compound annual growth rate of 8.36%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 16, 2026 | 45.14B | 45.57% |
| Dec 31, 2025 | 31.01B | 140.72% |
| Dec 31, 2024 | 12.88B | 70.50% |
| Dec 29, 2023 | 7.55B | 8.59% |
| Dec 30, 2022 | 6.96B | -41.95% |
| Dec 31, 2021 | 11.98B | -53.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Sep 25, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| RemeGen | 80.10B |
| 3SBio | 57.55B |
| Biocytogen Pharmaceuticals (Beijing) | 46.28B |
| Shanghai Junshi Biosciences | 43.09B |
| InnoCare Pharma | 30.13B |
| Shanghai Bao Pharmaceuticals | 29.29B |
| Genscript Biotech | 27.79B |
| TransThera Sciences (Nanjing) | 27.75B |